X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs VENUS REMEDIES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA VENUS REMEDIES SUN PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 28.4 -1.4 - View Chart
P/BV x 3.0 0.1 2,911.5% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 SUN PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
VENUS REMEDIES
Mar-18
SUN PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs701126 556.4%   
Low Rs43361 709.0%   
Sales per share (Unadj.) Rs110.4301.8 36.6%  
Earnings per share (Unadj.) Rs11.0-24.9 -44.1%  
Cash flow per share (Unadj.) Rs17.22.5 677.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8293.3 54.1%  
Shares outstanding (eoy) m2,399.2612.34 19,442.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.3 1,657.2%   
Avg P/E ratio x51.6-3.8 -1,373.5%  
P/CF ratio (eoy) x32.936.7 89.5%  
Price / Book Value ratio x3.60.3 1,119.7%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,154 117,874.2%   
No. of employees `00017.80.9 1,923.1%   
Total wages/salary Rs m53,671393 13,653.1%   
Avg. sales/employee Rs Th14,890.94,026.1 369.9%   
Avg. wages/employee Rs Th3,017.1425.0 709.9%   
Avg. net profit/employee Rs Th1,480.6-331.8 -446.2%   
INCOME DATA
Net Sales Rs m264,8953,724 7,113.0%  
Other income Rs m8,38823 37,278.2%   
Total revenues Rs m273,2823,747 7,294.1%   
Gross profit Rs m56,081395 14,205.0%  
Depreciation Rs m14,998338 4,433.5%   
Interest Rs m5,176354 1,460.8%   
Profit before tax Rs m44,295-275 -16,089.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,45232 26,746.5%   
Profit after tax Rs m26,338-307 -8,581.9%  
Gross profit margin %21.210.6 199.7%  
Effective tax rate %19.1-11.5 -166.2%   
Net profit margin %9.9-8.2 -120.7%  
BALANCE SHEET DATA
Current assets Rs m316,3592,638 11,993.8%   
Current liabilities Rs m198,6432,305 8,619.2%   
Net working cap to sales %44.48.9 496.9%  
Current ratio x1.61.1 139.2%  
Inventory Days Days95135 70.0%  
Debtors Days Days10846 232.4%  
Net fixed assets Rs m213,1784,871 4,376.7%   
Share capital Rs m2,399123 1,944.3%   
"Free" reserves Rs m378,6063,496 10,830.7%   
Net worth Rs m381,0063,619 10,527.6%   
Long term debt Rs m17,7211,374 1,289.4%   
Total assets Rs m643,0287,509 8,564.0%  
Interest coverage x9.60.2 4,286.7%   
Debt to equity ratio x00.4 12.2%  
Sales to assets ratio x0.40.5 83.1%   
Return on assets %4.90.6 776.3%  
Return on equity %6.9-8.5 -81.5%  
Return on capital %10.01.6 633.6%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m40,8160-   
Fx outflow Rs m30,143517 5,836.1%   
Net fx Rs m10,673-517 -2,066.4%   
CASH FLOW
From Operations Rs m39,072514 7,595.5%  
From Investments Rs m-33,708-123 27,382.7%  
From Financial Activity Rs m-15,393-387 3,976.4%  
Net Cashflow Rs m-7,3594 -175,216.7%  

Share Holding

Indian Promoters % 63.7 32.9 193.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.2 2,850.0%  
FIIs % 23.0 0.6 3,965.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 66.4 12.5%  
Shareholders   133,026 20,121 661.1%  
Pledged promoter(s) holding % 0.5 36.4 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Rupee Hits 70-Mark Again(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is flat.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 25, 2019 10:05 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS